Girard I, Ferry S
Unité de Pharmacologie Clinique, Unité de Phase I: Hôpital Cardiologique, Lyon, France.
J Pharm Biomed Anal. 1996 Mar;14(5):583-91. doi: 10.1016/0731-7085(95)01636-8.
This paper describes the parameters that characterize methohexital-albumin binding and the influence of physiological or analytical factors on this binding. Two useful and reproducible methods for measuring the free concentration-equilibrium dialysis (ED) and ultrafiltration (UF)-are described and their performances are compared. Methohexital binds exclusively to albumin according to a two-class binding model. The first is a saturable class site of high affinity constant (KA = 11 200 M-1) and a number of sites per albumin molecule of 1. The second is a non-saturable site of poorer affinity (nKA = 810 M-1). The bound fraction of methohexital in the therapeutic range and at physiological albumin concentration is 86.7 +/- 0.9% in isolated albumin solution. In serum, it ranges from 80 to 84.5%, according to subjects (n = 6). Binding is inhibited by the presence of endogenous compounds of serum (for a given albumin concentration the bound fraction decreases from 90.3% in isolated albumin solution to 82.6% in serum), probably by free fatty acids. An increase in the bound fraction is observed when the pH is increased from 7 to 9. This phenomenon may be explained by a higher affinity of the drug towards the basic (B-form) conformation of the albumin molecule, in analogy with the close barbiturate thiopental. A decrease in the bound fraction against temperature is shown, as though binding forces diminished with increase in temperature. Indeed, the binding modification is less pronounced in the presence of serum endogenous compounds. As expected, there is no evidence of any effect of heparin anticoagulant on the bound fraction. Methohexital binding is strongly modified by the albumin concentration; the bound fractions change from 67 to 91% in the albumin range 150-900 microM.
本文描述了表征甲己炔巴比妥 - 白蛋白结合的参数以及生理或分析因素对这种结合的影响。介绍了两种用于测量游离浓度的有用且可重复的方法——平衡透析(ED)和超滤(UF),并比较了它们的性能。根据两类结合模型,甲己炔巴比妥仅与白蛋白结合。第一类是具有高亲和常数(KA = 11200 M⁻¹)的可饱和位点,每个白蛋白分子的位点数量为1。第二类是亲和力较差的非饱和位点(nKA = 810 M⁻¹)。在治疗范围内且生理白蛋白浓度下,甲己炔巴比妥在分离的白蛋白溶液中的结合分数为86.7±0.9%。在血清中,根据受试者(n = 6),其范围为80%至84.5%。血清内源性化合物的存在会抑制结合(对于给定的白蛋白浓度,结合分数从分离的白蛋白溶液中的90.3%降至血清中的82.6%),可能是由游离脂肪酸引起的。当pH从7增加到9时,观察到结合分数增加。这种现象可能是由于药物对白蛋白分子碱性(B型)构象的亲和力更高,类似于密切相关的巴比妥类药物硫喷妥钠。显示出结合分数随温度降低,好像结合力随温度升高而减弱。实际上,在存在血清内源性化合物的情况下,结合修饰不太明显。正如预期的那样,没有证据表明肝素抗凝剂对结合分数有任何影响。甲己炔巴比妥的结合受到白蛋白浓度的强烈影响;在白蛋白浓度范围为150 - 900 microM时,结合分数从67%变为91%。